… However, new evidence has cautioned the use of beta-blockers in patients with end-stage …
effects of beta-blocker therapy, the potential harms of aggressive beta-blocker therapy, and …

… Beta blockers with ISA lower HR less than β blockers without ISA and provide less …
Beta-blocker therapy should not be abruptly discontinued in patients with CAD, as this may …

… function after treatment with beta-blockers, the exercise capacity and … beta-blocker therapy.
Prospective trials to clarify the impact of betablocker therapy and the optimal therapeutic …

… first-line therapy? Nowadays, many physicians believe that β-blockers (BBs) are the most
protective class of drugs for heart and brain and consider them as the most effective therapy in …

… β-Blocker therapy should also be considered in asymptomatic patients with large areas of
ischemia (level IIa C evidence) and in microvascular angina to improve effort-related angina …

… BETA BLOCKERS Beta blockers have been used in the treatment of hypertension for well
over 2 decades. They were accepted as first-line treatment in many centers in the early 1970s …

… In general, therapy in CHF patients is initiated with an ACE inhibitor or an AngII-receptor
blocker (ARB), and thereafter a β-blocker is introduced. This drug sequence seems to result …

… β-blocker therapy in cardiac diseases and arrhythmias, such as atrial fibrillation (AF),
myocardial infarction (MI), and heart failure (HF). We suggest key questions and aspects that future …

… to the role of β-blockers in heart failure therapy. Despite its limitations and negative mortality
results, the MDC trial sparked renewed interest in β-blockers as a therapy for heart failure. …

Head injury remains the leading cause of death among trauma patients and accounts for
one-third of all trauma mortalities. 1, 2 Of these, 75% will die within the first 3 days. In patients …